News

Mr Hutt has represented national trade associations for the food, prescription drug, nonprescription drug, dietary supplement, and cosmetic industries, and has been a member of the Institute of

Jack Saladow, vice president of marketing and sales at Ivera, said: “The licensing agreement between Becton, Dickinson and Company (BD) and Ivera broadens our existing patent applications and

Mr Eyal most recently served as executive vice president at NUR Macroprinters, a manufacturer of super-wide format digital printers and inks. He holds a BSc in engineering and

The partnership is expected to enable a seamless integration of study conduct with full CRO services, including project management, monitoring, quality assurance, data management, biostatistics, and medical writing.

This deal exercises an option agreement signed in February 2007 between the two companies and provides Novosom with exclusive, worldwide and sub-licensable access to certain of Isis’s proprietary

The company will issue 23.81 million shares at A$0.105 per share. Participants in the placement include OppenheimerFunds and other US and Australian investors. Proceeds are being allocated to

Dr Chada will report directly to Intrexon’s CEO, Robert Beech and will be responsible for all aspects of the company’s pre-clinical and clinical development programs. Dr Chada’s biotechnology

Den-Mat will acquire the rights to Remedent’s single-motion veneer placement tray technology, proprietary veneer fabrication technique, and computer imaging design and digital preview technology. According to Den-Mat, integrating

Arch Venture Partners, Bain Capital Ventures, and Flagship Ventures co-led the round. Proceeds from the financing will be used to validate the platform and accelerate development of ultrasensitive